Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Predictive Role of Tumour Markers in Patients with Advanced-stage Non Small Cell Lung Cancer (NSCLC) Treated with tyrosinkinase inhibitors (TKIs), bevacizumab and pemetrexed:TULUNG registry

Trial Profile

A Study to Evaluate the Predictive Role of Tumour Markers in Patients with Advanced-stage Non Small Cell Lung Cancer (NSCLC) Treated with tyrosinkinase inhibitors (TKIs), bevacizumab and pemetrexed:TULUNG registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Alectinib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Durvalumab (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Lorlatinib (Primary) ; Nintedanib (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Trametinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2021 Results assessing the prognostic and predictive value of EGFRExon-20 insertions in Czech patients with advanced non-small cell lung cancer, published in the Anticancer Research.
    • 01 Apr 2021 Results (N=105) of an analysis assessing the prognostic role for CYFRA 21-1 in patients with advanced-stage NSCLC treated with Bevacizumab plus chemotherapy, published in the Anticancer Research
    • 10 Sep 2019 Results from 1st line treatment patients (n=470) presented at the 20th World Conference on Lung Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top